MaxCyte, Inc. (NASDAQ:MXCT) Short Interest Update

MaxCyte, Inc. (NASDAQ:MXCT) was the recipient of a significant increase in short interest in February. As of February 13th, there was short interest totaling 5,092,073 shares, an increase of 31.2% from the January 29th total of 3,881,689 shares. Currently, 4.9% of the company’s stock are short sold. Based on an average daily volume of 1,727,932 shares, the short-interest ratio is presently 2.9 days. Based on an average daily volume of 1,727,932 shares, the short-interest ratio is presently 2.9 days. Currently, 4.9% of the company’s stock are short sold.

MaxCyte Price Performance

NASDAQ:MXCT traded down $0.02 during trading hours on Monday, reaching $0.79. 1,054,866 shares of the company traded hands, compared to its average volume of 1,436,582. MaxCyte has a 1-year low of $0.64 and a 1-year high of $3.58. The stock has a market cap of $84.07 million, a P/E ratio of -1.79 and a beta of 1.22. The firm’s 50-day moving average is $1.11 and its 200-day moving average is $1.40.

Hedge Funds Weigh In On MaxCyte

A number of institutional investors have recently made changes to their positions in the business. Mirabella Financial Services LLP boosted its holdings in MaxCyte by 78.4% during the second quarter. Mirabella Financial Services LLP now owns 6,600,000 shares of the company’s stock worth $14,388,000 after buying an additional 2,900,000 shares in the last quarter. Kennedy Capital Management LLC acquired a new stake in MaxCyte during the third quarter valued at $3,330,000. AXA S.A. increased its stake in shares of MaxCyte by 123.2% during the 2nd quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock worth $4,801,000 after purchasing an additional 1,215,481 shares during the last quarter. Millennium Management LLC grew its stake in MaxCyte by 1,082.6% in the 4th quarter. Millennium Management LLC now owns 1,292,773 shares of the company’s stock valued at $2,004,000 after buying an additional 1,183,461 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in shares of MaxCyte in the fourth quarter valued at about $1,594,000. 68.81% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have commented on MXCT shares. Wall Street Zen raised MaxCyte from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of MaxCyte in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $7.00.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.